PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Enterprise Therapeutics Doses First Person with Cystic Fibrosis in ...
WEBJul 23, 2024 · Trial aims to deliver clinical proof-of-concept and assess the safety profile of novel long acting ENaC inhibitor ETD001; ETD001, a CFTR mutation agnostic approach to CF, is focussed on providing a novel treatment for members of the CF community that do not benefit from currently available mutation-targeted therapies
TREMFYA® (guselkumab) receives U.S. FDA approval for adults …
WEBSep 12, 2024 · The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program 1,2,3,4,5. TREMFYA ® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis. HORSHAM, PA, USA I September 11, 2024 I Johnson ...
U.S. Food and Drug Administration Approves Bristol Myers …
WEBSep 27, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Small Molecules - Pipelinereview
WEBSep 26, 2024 · Small Molecules. 4 October 2024. First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer. 2 October 2024. Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a ...
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND …
WEB3 days ago · SOUTH SAN FRANCISCO, CA, USA I October 04, 2024 I Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference with the U.S. Food and Drug Administration (FDA) that the zetomipzomib Investigational New Drug (IND) application for the ...
Pinetree Therapeutics Announces Exclusive Option and Global …
WEBJul 24, 2024 · Pinetree to receive up to $45 million in upfront and near-term payments, with a total deal value of over $500 million including potential additional development and commercial milestone payments
The convergence of Antibody-Drug Conjugates and Targeted …
WEBSep 4, 2024 · STUTTGART, Germany I September 04, 2024 I La Merie Publishing released its newest report with a landscape description and analysis of degrader-antibody conjugate (DAC) stakeholders, platform technologies, development and discovery pipelines and partnering deals from an industry perspective as of September 2024:. Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders ...
Johnson & Johnson seeks first EU approval of nipocalimab to treat …
WEBSep 12, 2024 · Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising …
WEBSep 16, 2024 · COPENHAGEN, Denmark I September 15, 2024 I Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an